The 7 major Usher syndrome markets reached a value of USD 1.20 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1.76 Billion by 2035, exhibiting a growth rate (CAGR) of 3.49% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 1.20 Billion |
Market Forecast in 2035
|
USD 1.76 Billion |
Market Growth Rate 2025-2035 | 3.49% |
The Usher syndrome market has been comprehensively analyzed in IMARC's new report titled "Usher Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Usher syndrome refers to a rare genetic disorder characterized by a combination of hearing loss or deafness and progressive vision loss. This condition primarily affects the inner ear, leading to varying degrees of hearing impairment, and also involves the gradual deterioration of vision due to retinitis pigmentosa, a degenerative eye disorder. The symptoms of the ailment can differ widely among patients and can occur during infancy or adulthood. Hearing loss or deafness is often present from birth or early childhood, and it can range from mild to profound. The vision loss associated with retinitis pigmentosa typically emerges later in childhood or adolescence, causing night blindness and a narrowing field of vision, ultimately leading to tunnel vision or complete blindness over time. The diagnosis of Usher syndrome involves comprehensive medical and genetic assessments. Audiological tests can determine the extent of hearing loss, while visual field tests and retinal imaging can help to identify retinitis pigmentosa.
The escalating prevalence of mutations in genes, such as MYO7A, USH1C, and CDH23, which are integral to the proper functioning of the auditory and visual systems, is primarily driving the Usher syndrome market. In addition to this, the inflating utilization of efficient therapeutic solutions, including cochlear implants for hearing loss and retinal implants for visual impairments, is also creating a positive outlook for the market. Moreover, the widespread adoption of audiological and ophthalmological rehabilitation techniques, since they help to improve the independence and quality of life for individuals suffering from the illness, is further bolstering the market growth. Apart from this, the growing research and development activities that are poised to uncover novel treatment modalities and medications, which can alleviate or even reverse the symptoms of Usher syndrome are acting as another significant growth-inducing factor. Additionally, the emerging popularity of antioxidant supplements, such as vitamin A and vitamin E, to slow down disease progression is also augmenting the market growth. Furthermore, the escalating application of gene therapy, since it involves delivering corrective genetic material to cells, thereby rectifying or replacing the faulty genes responsible for the disorder, is expected to drive the Usher syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Usher syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Usher syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Usher syndrome market in any manner.
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current usher syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
AAVB-081 | AAVantgarde Bio Srl |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Usher Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies